|
イワモト タカユキ
Takayuki Iwamoto
岩本 高行 所属 川崎医科大学 医学部 臨床医学 乳腺甲状腺外科学 職種 講師 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy. |
| 掲載誌名 | 正式名：PloS one 略 称：PLoS One ISSNコード：19326203/19326203 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 17(11),pp.e0278344 |
| 著者・共著者 | Kikawa Yuichiro, Hagiwara Yasuhiro, Fujisawa Tomomi, Araki Kazuhiro, Iwamoto Takayuki, Sangai Takafumi, Shien Tadahiko,Takao Shintaro, Nishimura Reiki, Takahashi Masato, Toyama Tatsuya, Aihara Tomohiko, Mukai Hirofumi, Taira Naruto |
| 担当区分 | 2nd著者 |
| 発行年月 | 2022/11 |
| 概要 | BACKGROUND:The HORSE-BC study previously demonstrated that second-line endocrine therapy (ET) for patients with acquired endocrine-resistant metastatic breast cancer (MBC) still provided a clinically meaningful benefit. Herein, we investigated the health-related quality of life (HRQOL) in the HORSE-BC study.METHODS:Patients with acquired endocrine-resistant MBC who were scheduled for second-line ET were recruited. The HRQOL was assessed at baseline, and 1 and 3 months after second-line ET initiation. To investigate the minimally important difference (MID) in the Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES), we evaluated the means and standard deviations for the distribution-based method, and differences in the change in HRQOL for the anchor-based method. We also investigated the association between FACT-ES total scores and clinical benefit.RESULTS:Overall, 56 patients were enrolled. Of these, 47 were analyzed. When defined as 1/3 standard deviation estimates based on the distribution method, the calculated MID was 5.9. The MIDs of the FACT-ES total scores based on the anchor method were 7.7 for decline and 4.1 for improvement. The MID decline proportions were 6.1% and 14.7% lower in patients who experienced clinical benefits than in those who did not at 1 and 3 months, respectively. The ratios of MID improvement in patients who experienced clinical benefits were 18.3% and 3.2% higher, respectively; the mean change in the FACT-ES total score from baseline improved in patients who experienced clinical benefits.CONCLUSIONS:Maintaining the HRQOL as determined by FACT-ES may be associated with clinical benefits in patients with acquired endocrine-resistant MBC treated with ET. |
| DOI | 10.1371/journal.pone.0278344 |
| PMID | 36445924 |